Skip to main content
AVBP
NASDAQ Life Sciences

ArriVent BioPharma Reports Reduced Q1 Net Loss, Strong Liquidity, and Ongoing ATM Sales

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$29.02
Mkt Cap
$1.346B
52W Low
$16.1
52W High
$32.14
52W Position info
80% above low
Off High info
9.7% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

AVBP sits 80% above its 52-week low of $16.1.

Summary

ArriVent BioPharma reported a reduced net loss for Q1 2026 and a strong liquidity position with a projected cash runway of at least 12 months, supported by ongoing ATM equity sales and an undrawn debt facility.


Key Events · Earnings and Guidance · AVBP

  • Reduced Net Loss

    Reported a net loss of $43.3 million for Q1 2026, a significant reduction from $64.4 million in Q1 2025. Diluted loss per share improved to $(0.96) from $(1.90) year-over-year.

  • Strong Liquidity and Cash Runway

    Ended Q1 2026 with $326.4 million in cash, cash equivalents, and marketable securities, which management believes is sufficient to sustain planned operations for at least 12 months from the filing date.

  • Active At-The-Market (ATM) Program

    Sold 2,425,495 shares of common stock through its ATM program during Q1 2026, generating $54.7 million in net proceeds. Approximately $66.9 million remains available under the $250 million program.

  • Undrawn Debt Facility

    Maintains access to a $75 million loan and security agreement with Silicon Valley Bank, amended in March 2026, with no amounts drawn as of March 31, 2026.


Analysis · AVBP · Life Sciences

This quarterly report provides a detailed financial update for ArriVent BioPharma. The company significantly reduced its net loss and operating cash burn year-over-year, primarily due to a one-time upfront payment in the prior year's R&D expenses. Despite this, R&D expenses remain substantial as the company advances its pipeline. The company's liquidity position is robust, with over $326 million in cash and investments, and management projects a cash runway of at least 12 months. The ongoing at-the-market equity program continues to provide capital, with $54.7 million raised in Q1, and a substantial undrawn debt facility offers further financial flexibility. A $6.0 million milestone payment was made for the ARR-217 program, indicating continued pipeline progress.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AVBP was trading at $29.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $16.10 to $32.14. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AVBP - Latest Insights

AVBP
Nov 09, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $10.78 info
Change: -$3.39 (-24%) info
Market Cap: $557.575M info
AVBP
Nov 09, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $10.78 info
Change: -$3.39 (-24%) info
Market Cap: $557.575M info
AVBP
Nov 09, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $10.78 info
Change: -$3.39 (-24%) info
Market Cap: $557.575M info
AVBP
Oct 26, 2026, 6:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.30
Real-time Price: $10.78 info
Change: -$12.53 (-54%) info
Market Cap: $557.575M info
AVBP
Oct 12, 2026, 5:29 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $16.46
Real-time Price: $10.78 info
Change: -$5.69 (-35%) info
Market Cap: $557.575M info